Prevention of atrial fibrillation
121 results
1 - 100
Low-dose edoxaban effective for stroke prevention for elderly patients with atrial fibrillation- Screening high-risk patients for atrial fibrillation with implantable loop recorder does not prevent stroke or systemic emboli (LOOP)
- For atrial fibrillation with stable coronary artery disease, edoxaban alone prevents more bad outcomes than edoxaban plus an antiplatelet agent
- For patients with subclinical intermittent atrial fibrillation, apixaban prevents 1 stroke and causes 1 major bleed per 250 persons (ARTESIA)
- Atrial fibrillation recurrence higher with episodic treatment with amiodarone
- Cryoablation preferred as initial therapy for paroxysmal atrial fibrillation (EARLY-AF)
- ARBs & ACE inhibitors prevent A fib
- Rhythm control is associated with a lower risk of cognitive decline than rate control in adults with atrial fibrillation
- USPSTF 2022 concludes evidence is insufficient to recommend screening for asymptomatic atrial fibrillation (I statement)
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant
- Dronedarone reduces hospitalization but not mortality in atrial fibrillation
- Percutaneous left atrial appendage closure reduces AF stroke risk
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Warfarin prevents more strokes than clopidorel+ASA in a fib (ACTIVE)
- Warfarin > aspirin in preventing strokes in pts older than 75 with A fib (BAFTA)
- Dronedarone prevents AF recurrence but effect on symptoms unknown
- The prognosis is similar for adults with symptomatic versus asymptomatic atrial fibrillation
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- Lenient = strict rate control in prevention of adverse outcomes in AF
- NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
- Dabigatran reduces risk of stroke and embolism in patients with AF
- Catheter ablation of AF prevents recurrence but has minimal impact on QOL
- Colchicine prevents postpericardiotomy syndrome following cardiac surgery
- Apixaban reduces stroke and embolism more than aspirin in A fib
- Benefits to resuming warfarin in patients with atrial fibrillation after intracranial bleeds
- ABC (Age, Biomarkers, Clinical history) score predicts stroke risk in atrial fibrillation
- No worsening of post-op atrial arrhythmias with relaxed potassium supplementation following coronary artery bypass grafting (TIGHT K)
- Fewer major bleeds with edoxaban than with warfarin, but treatment benefit unclear (ENGAGE-AF)
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Warfarin superior to antiplatelet treatment for A Fib
- Screening for atrial fibrillation in primary care is not effective (VITAL-AF)
- USPSTF 2018: insufficient evidence to recommend screening for AFib with ECG (I statement)
- Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- Early anticoagulation after ischemic stroke is a safe strategy (ELAN)
- Beta-blockers don't decrease mortality in patients with AF + CHF
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Prescription omega-3 fatty acids do not reduce risk of recurrent A fib
- In adults with atrial fibrillation and acute ischemic strokes, early (within 4 days) and delayed (7-10 days) initiation of DOACs have similar outcomes (OPTIMAS)
- Rivaroxaban similar to warfarin for patients with NVAF
- AHA guideline for secondary stroke prevention
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- New anticoagulants vs warfarin in A fib: no clear winner
- Increased GI bleeding after switch from warfarin to dabigatran
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- No reduction in stroke recurrence with apixaban vs aspirin in patients with cryptogenic stroke and atrial cardiopathy (ARCADIA)
- Bleeding risk with warfarin high among elderly, especially older than 80
- Radiofrequency ablation an option for healthy younger patients with paroxysmal AF